$3.11
+0.12 (+4.01%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SIGA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 1 observational · 7 with posted results
Held by 13 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, Qube Research & Technologies Ltd, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, +8 more) · FINRA short interest 3.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSNCT04957485Adverse EventsRandomized · Double-masked · Treatment | Phase 2 | Active, not recruiting | Drug: Tecovirimat, Smallpox and Mpox Vaccine · Other: Placebo | Smallpox | 100 | 2027-01-01 | in 134 d | 2026-04-02 |
| A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With SmallpoxNCT03972111observationalAssess survival | — | Withdrawnsponsor's stated reason: commitment fulfilled | Drug: TPOXX 200Mg Capsule | Smallpox | 0 | 2024-09-30 | — | 2022-10-03 |
| Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 DaysNCT04971109results2024-10-23CminRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: TPOXX · Other: TPOXX Placebo | Smallpox | 467 | 2023-05-12actual | — | 2024-12-27 |
| Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate BindersNCT04485039results2024-10-09AUC0-infRandomized · Open-label · OtherStudy Protocol and Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet, calcium acetate oral tablet, Lanthanum Carbonate Chewable Tablet | Smallpox | 44 | 2022-12-15actual | — | 2024-12-27 |
| Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KGNCT04392739results2024-09-19AUC0-tOpen-label · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 4 | Completed | Drug: Tpoxx | Smallpox | 34 | 2019-12-05actual | — | 2024-09-19 |
| A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound TecovirimatNCT02474589results2017-11-28To Determine the Number of Participants With Adverse EventsRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: tecovirimat · Other: Placebo | Smallpox | 449 | 2016-08-24actual | — | 2017-11-28 |
| Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246NCT00907803results2010-08-27Number of Study Participants Who Tolerated a Single Daily Oral ST-246 Dose as Determined by Safety Parameter Changes According to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.Randomized · Double-masked | Phase 2 | Completed | Drug: ST-246 400 mg, ST-246 600 mg, Placebo | Orthopoxviral Disease | 107 | Jan 2010actual | — | 2010-09-21 |
| Phase I Trial of an Investigational Small Pox MedicationNCT00728689results2010-02-09Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½Randomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: ST-246 Days 1 - 3, ST-246 Days 11 - 13 | Orthopoxviral Disease, Smallpox, Monkey Pox | 12 | Oct 2008actual | — | 2015-06-29 |
| Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy VolunteersNCT00431951results2010-05-07Number of Study Participants Who Tolerated ST-246 (250, 400 or 800mg) as Determined by Changes in Safety Parameters, According to the Division of Acquired Immunodeficiency Syndrome (DAIDS) Adverse Events (AE) Grading TableRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: ST-246, Placebo | Healthy | 30 | Feb 2008actual | — | 2017-07-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19